Introduction
Expression of recombinant mammalian proteins is at the heart of structural studies in the biomedical field and is also important to commercial biotherapeutics, particularly the expression of antibodies. Although cloning, expression and production methods are available for many hosts [1] [2] [3] , there is an ongoing effort to improve expression through traditional bioprocess optimization and cell reengineering, especially for low yielding targets such as membrane proteins, large protein complexes and posttranslationally modified proteins [4, 5] . The first step in any strategy to over-produce proteins is the selection of the expression host. According to statistics from the Protein Data Bank (http://www.rcsb.org) and the 'Membrane Proteins of Known Structure Database' (http:// blanco.biomol.uci.edu/mpstruc/), of all the proteins that had their structures determined between 2004 and 2013, 78% were expressed in Escherichia coli and only 4% in insect cells ( Figure 1A ). However, for the overexpression of membrane proteins, E. coli was utilized on average less (61%) and eukaryotic expression systems were used comparatively more ( Figure 1B) . Notably, there is an increasing trend in the use of more complex eukaryotic hosts (insect and mammalian cells, Figure 1C ), which reflects an increase in the number of mammalian membrane proteins being crystallized, particularly G proteincoupled receptors (GPCRs) [6] .
Despite many successes in the production of sufficient protein for crystallization and structure determination, proteins from, for example, mammalian sources and/or are integral membrane proteins are often difficult to overexpress [4, 7] . Host cell engineering has emerged as one effective strategy for improving recombinant protein yields ( Table 1 ) that can overcome bottlenecks in different steps along the protein production process. Here we discuss some recent successful cases that target potential bottlenecks in protein production, using strategies focused on optimizing transcription/translation, engineering the folding and secretory pathways, mutating the target protein sequence, and enhancing cell proliferation and/or survival.
Optimizing transcription and enhancing translation
One of the most important choices in planning a strategy for overexpression of proteins is the type of promoter to use, and it is often the case that the strongest promoter will be the best for producing large amounts of correctly folded protein. Thus the most commonly used promoters are the T7 promoter in E. coli, the polyhedrin promoter in the baculovirus expression system and the CMV promoter in mammalian cells. If transcription is the rate limiting step in protein production, even after choosing a strong promoter, then increasing further the strength of the promoter may be effective. For example, Quilici et al. constructed a strong CMV promoter variant through introducing a 200-nucleotide deletion of intron A that increased luciferase expression up to 2-fold in mammalian cells [8] . However, recent studies have shown that increasing the amount of mRNA encoding the protein of interest does not necessarily lead to improved protein production in E. coli [9 ] or insect cells [10] . In these instances, it is possible that the rate limiting step is protein folding, perhaps due to limitations in host cell factors, such as molecular chaperones. Enhancements in protein expression can be achieved through reducing the rate of transcription, either by substituting a strong promoter with a weaker one [9 ,10] , or by weakening a strong promoter by introducing a point mutation [11 ] . An alternative approach is to reduce the levels of polymerase in the host cell. For example, the levels of the T7 DNA polymerase expressed in E. coli can be modulated by altering the expression levels of the natural inhibitor T7 lysozyme, which is under the control of a tightly regulated inducible promoter, hence fine-tuning the rates of transcription. Wagner et al. improved expression of 14 membrane proteins using this methodology [12] .
Even when strong promoters are used, host cell factors can result in low rates of transcription. For example, during the construction of stable mammalian cell lines with the gene of interest expressed from the CMV promoter, poor expression could result from epigenetic silencing of the promoter. This can be alleviated by engineering the nuclear matrix attachment region (MAR) [13] or by combining a MAR with a mammalian replication initiation region (IR) [14, 15 ], consequently improving recombinant protein production in mammalian cell lines.
Translation of the gene of interest may also be inhibited by host cell silencing processes during protein production. For example, eukaryotic translation initiation factor 2 may become phosphorylated after DNA plasmid transfection or upon virus transduction, which will inhibit translation and thus decrease protein expression. However, viruses have evolved mechanisms to circumvent this. Gantke et al. co-expressed the Ebola virus protein 35, which is a viral protein that prevents translational silencing, and increased recombinant protein production by 10-fold [16 ]. An alternative approach to circumvent translational silencing in insect cells following baculovirus infection is to co-express eIF4E, which resulted in a 2-fold increase in the production of a secreted alkaline phosphatase (SEAP)-EGFP fusion protein (SEFP) [17] .
Folding and secretory pathway engineering
Molecular chaperones have been applied to improve protein production in various systems, where they act to preserve nascent proteins in a folding-competent conformation and prevent aggregation [18] . The most extensively used chaperone systems that have facilitated protein production in E. coli are DnaK-DnaJ-GrpE and GroEL-GroES [19, 20] . In insect cells, host protein biosynthesis shuts down as a result of infection by the recombinant baculovirus, which can adversely affect levels of molecular chaperones important for the folding of secreted proteins and membrane proteins in the endoplasmic reticulum (ER), particularly in relation to the high levels of protein synthesis resulting from high mRNA levels produced from the polyhedrin promoter. Hence, co-expression of the membrane-bound molecular chaperone calnexin enhanced the expression of functional serotonin transporter (SERT) by nearly 3 fold [21] , and co-expression of the soluble molecular chaperone calreticulin increased secretion of SEFP in insect cells [17] . Whether a lack of appropriate molecular chaperones in heterologous systems contributes to low levels of functional protein sometimes is difficult to assess. However, overproduction of mammalian calnexin in the yeast Hansenula polymorpha did increase production of the truncated glycoprotein of rabies virus [22] , suggesting that at least in this case the folding environment in the yeast ER was not optimal for folding large amounts of glycoprotein.
However, co-expression of molecular chaperones is not a panacea and does not often give a 10-fold or more improvement in expression levels. Part of the problem is that overexpression of ER resident chaperones such as calreticulin might burden the ER and activate an unfolded protein response [17] . Another more challenging issue is that molecular chaperones may act in a concerted fashion to promote protein folding in a poorly understood process, suggesting that it may be best to overexpress multiple chaperones simultaneously. However, expression levels will need to be tightly controlled to prevent overwhelming the cells protein production resource and also the stoichiometry between chaperones will have to be regulated. Another problem associated with engineering the chaperone and secretory pathway is that it can be protein and host specific. For example, coexpression of protein disulfide isomerase increased yields of albumin fusion proteins in the yeast Pichia pastoris [23 ] but did not improve functional SERT expression in insect cells [21] . Similarly, SRP 14 overexpression led to a substantial improvement of IgG production in CHO cells, but the strategy was ineffective in human cell lines producing alkaline phosphatase [24, 25] .
An alternative strategy to overexpressing molecular chaperones is to delete endogenous competing chaperones in order to channel the nascent peptide chain to the desired signal recognition particle (SRP) secretory pathway. Indeed, Nannenga et al. showed that membrane protein insertion in E. coli improved and expression levels increased through eliminating competition between trigger factor (TF) and the signal recognition particle (SRP) for the nascent polypeptide chain [11 ,26 ] .
Another strategy to improve secretion is to improve vesicular trafficking from the ER to the cell surface. Co-expression of secretory proteins which modulate vesicle trafficking, such as soluble NSF receptor (SNARE) proteins (SNAP-23 or VAMP8), improved production of SEAP and monoclonal antibodies by 2-3 fold in mammalian CHO-K1 cells [27] . Likewise, overexpression of SNARE-interacting Sec1p and Sly1p proteins improved expression of a-amylase and human insulin precursor in Saccharomyces cerevisiae [28] . In addition, the ceramide transfer protein S132A mutant improved production of tissue-plasminogen activator (t-PA) [29] , human serum albumin (HSA) and monoclonal antibodies in CHO [30] .
Protein sequence mutagenesis
Mutating the sequence of the protein target can also improve expression levels of the target protein. Sometimes this may be achieved through rational approaches such as analyzing the structure of the protein, as in the D500G mutation of laccase in E. coli [31] and the cysteine mutation of coagulation factor VIII [32 ] . However, in many instances there is insufficient evidence to suggest why a protein does not overexpress, so high-throughput mutagenic strategies can be used. For example, directed evolution coupled with random mutagenesis, followed by screening and selection was used by Sarkar et al. to evolve a GPCR, the rat neurotensin receptor (NTR) in E. coli. A mutant with 14 nucleotide substitutions retained the biochemical properties of the wild type receptor together with a 10-fold increase in functional expression and slightly increased thermostability [33] . Similarly, Heggeset et al. applied combinatorial mutagenesis and selection based on ampicillin tolerance in E. coli to evolve the signal sequence of b-lactamase and improved SEAP production up to 8-fold [34 ] .
In theory, a more elegant and simple strategy would be to use in vivo mutagenesis coupled to screening or selection to improve expression. This approach was used by Majors et al. to evolve an anti-apoptotic gene Bcl-x L in a mammalian expression system by harnessing the somatic hypermutation capability of human Ramos B-cell line. The Bcl-x L gene, coupled to the YFP reporter, was mutated 'in situ' and subjected to rounds of staurosporine treatment to identify mutants with reduced apoptosis activation and higher YFP-Bcl-x L expression levels [35] .
Cell proliferation and survival engineering
The delay or prevention of the apoptosis cascade activation has been successful in preventing cell death and improving protein production in CHO cells under stress conditions [36] . Co-expression of the anti-apoptotic protein Bcl-x L in CHO cells improved the expression of epidermal growth factor receptor, fibroblast growth factor receptor 3 and receptor tyrosine kinases proteins [37] . Knock-out of the genes encoding the pro-apoptotic factors Bax and Bak in a CHO-K1 cell line improved cell viability, reduced levels of transfection-induced apoptosis and led to up to 4 fold higher antibody titers [38 ] . Similarly, knock-out of the pro-apoptotic microRNA mmu-miR-466h-5p in CHO cells delayed the onset of apoptosis, increased the maximum viable cell density and enhanced expression of SEAP [39 ] .
Enhanced cell proliferation represents another potential approach to increase biomass and obtain higher Cell engineering to improve protein expression Xiao, Shiloach and Betenbaugh 35 Other strategies Lysozyme Intracellular E. coli 3000 [44 ] volumetric yield during large scale production processes. For example, a metabolically engineered respiratory strain of S. cerevisiae (TM6*) doubled volumetric yield of Fps1 and at least quadrupled the yield of two human GPCRs (A 2a R and CNR2) [40] . Overexpression of the mammalian target of rapamycin (mTOR) simultaneously improved cell growth, proliferation, viability and specific productivity of antibody, SEAP and secreted a-amylase in CHO cells [41] . Similarly, overexpression of miR-7 in CHO cells enhanced cell proliferation, leading to higher Epo-Fc titer [42] . However, accumulated biomass does not always lead to increased production as demonstrated by chemical inhibition of autophagy in CHO cells, which led to decreased cell concentration but a 2.8-fold increase in t-PA [43 ] .
Other strategies
In cases where the heterologous proteins are toxic to the host cells, the presence of inhibitors can protect the host by sequestering proteins and keeping them in an inactive state. For example, co-expression of lysozyme together with its inhibitor Ivy, repressed lysozyme lytic activity in cytoplasm, and, along with transcription enhancement and chaperone co-expression, remarkably improved soluble lysozyme production in E. coli [44 ] .
Conclusion
Recombinant protein expression has facilitated biochemical and structural studies of thousands of naturally low abundance proteins. Methodologies that improve expression levels can be particularly advantageous for many difficultto-produce proteins or if the protein is being produced for therapeutic or industrial purposes. To improve expression levels further through cell engineering requires an understanding of both the host organism and the biology of protein expression. Considerable effort has been focused on engineering E. coli and yeast strains, and now there is an expanding effort to engineer insect and mammalian hosts such as HEK293 and CHO cell lines [45, 46, 47 ] , especially for functional expression of mammalian membrane proteins that include particularly complex folding, assembly, and processing pathways [48] [49] [50] . However, in many instances there is only limited information on the factors that affect expression of any particular protein, so current strategies are often piecemeal and focus on only one or two aspects of the protein production process. A goal for the future is robust cell factories generated through a holistic approach that considers all the bottlenecks in the protein expression process such as transcription, translation, protein folding, secretion and cell viability and engineer these through an integrative process to enable high-level expression of a wide spectrum of target proteins.
